Magenta Therapeutics, Inc. (MGTA)

Trade MGTA now with
8/6/2020 8:10:37 AM Magenta Therapeutics Q2 Net Loss $19.1 Mln Vs. Net Loss $17.7 Mln Last Year
6/15/2020 6:04:25 AM Magenta, Beam Therapeutics Announce Non-exclusive Collaboration Agreement To Evaluate Potential Utility Of MGTA-117
6/5/2020 8:34:06 AM Magenta Therapeutics Presents Data Supporting Immune Reset For Autoimmune Diseases
5/7/2020 7:58:36 AM Magenta Therapeutics Q1 Loss Per Share $0.51 Vs $0.44 Last Year
4/17/2020 8:16:03 AM Magenta Therapeutics Promotes John Davis To Head Of Research And Development And Chief Medical Officer
3/3/2020 8:31:39 AM Magenta Therapeutics Q4 Net Loss $23.2 Mln Vs Loss $16.7 Mln Last Year
2/24/2020 8:34:56 AM Magenta Closes Dosing In Phase1 MGTA-145 Trial,showing Rapid,Single-Day First Line Stem Cell Mobilization And Collection
2/20/2020 8:38:40 AM Magenta Therapeutics Announces Updated Clinical Data From Phase 2 Trials Of Its Cell Therapy, MGTA-456
2/5/2020 8:45:48 AM Magenta Appoints Kristen Stants As Chief People Officer And Li Malmberg As SVP, Head Of Manufacturing
10/16/2019 8:37:30 AM Magenta Names Jan Pinkas As SVP, Head Of Translational Sciences; Chief Scientific Officer Mike Cooke To Leave
6/24/2019 4:21:11 PM Magenta Therapeutics Appoints Anne McGeorge To Board Of Directors
5/10/2019 7:50:46 AM Wedbush Is Increasing Magenta Therapeutics, Inc. (MGTA) FY19 Estimate To -1.97 From -2.49
5/10/2019 7:50:32 AM Wedbush Is Raising Magenta Therapeutics, Inc. (MGTA) Q4 19 Estimate To -0.53 From -0.67
5/10/2019 7:50:09 AM Wedbush Is Raising Magenta Therapeutics, Inc. (MGTA) Q3 19 Estimate To -0.48 From -0.60
5/10/2019 7:49:56 AM Wedbush Is Raising Magenta Therapeutics, Inc. (MGTA) Q2 19 Estimate To -0.51 From -0.63
5/10/2019 7:49:24 AM Wedbush Reiterates Magenta Therapeutics, Inc. (MGTA) At Outperform With $22 Price Target
5/9/2019 7:37:58 AM Magenta Therapeutics Presents Updated Phase 2 Clinical Data On MGTA-456 Cell Therapy At AAN Annual Meeting